 |
Case Series
Association of BRCAness with taxane resistance in triple-negative breast cancer: A study of 7 cases
1 MD, Lecturer, Department of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan
2 MD, Assistant Professor, Department of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan
3 MD, Associate Professor, Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan
4 MD, Medical Director, Department of Breast Surgery, The Second Kawasaki Saiwai Clinic, 39-1 Miyako-cho, Saiwai-ku, Kawasaki-shi, Kanagawa, Japan
5 MD, Chief Professor, Department of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan
Address correspondence to:
Fuyo Kimura
Department of Breast Oncology and Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023,
Japan
Message to Corresponding Author
Article ID: 100089Z10FK2021
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Kimura F, Teraoka S, Sato E, Miyahara K, Nakamura Y, Ishikawa T. Association of BRCAness with taxane resistance in triple-negative breast cancer: A study of 7 cases. J Case Rep Images Oncology 2021;7:100089Z10FK2021.ABSTRACT
Introduction: Chemotherapy is the only systemic treatment option for triple-negative breast cancer (TNBC) patients, and is often used in combination with anthracycline and taxane. However, it was reported that many TNBCs show BRCA dysfunction, and are sensitive to DNA-damaging agents, but tend to be resistant to mitotic poisons, such as taxanes.
Case Series: Triple-negative breast cancer patients who underwent neoadjuvant chemotherapy with anthracycline followed by taxane were analyzed. Clinical responses to taxane were evaluated by the percentage of shrinkage in tumor size after anthracycline treatment. BRCAness was analyzed by mutiplex ligation-dependent probe amplification (MLPA) in core-needle biopsy specimens of 7 patients with progressive disease or stable disease after taxane treatment. BRCAness scores of the 7 patients were between 0.779 and 1.000 (0.939 ± 0.084), and all were categorized as having BRCAness.
Conclusion: Patients resistant to taxane were categorized as having BRCAness by MLPA. Mutiplex ligation-dependent probe amplification may hence be a promising method to identify TNBC patients with taxane resistance.
Keywords: BRCAness, Resistance, Taxane, Triple-negative breast cancer
SUPPORTING INFORMATION
Acknowledgments
We thank the Department of International Medical Communications of Tokyo Medical University for reviewing and editing the manuscript.
Author ContributionsFuyo Kimura - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Saeko Teraoka - Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Eiichi Sato - Substantial contributions to conception and design, Acquisition of data, Drafting the article, Final approval of the version to be published
Kana Miyahara - Substantial contributions to conception and design, Acquisition of data, Drafting the article, Final approval of the version to be published
Yukiko Nakamura - Substantial contributions to conception and design, Acquisition of data, Drafting the article, Final approval of the version to be published
Takashi Ishikawa - Substantial contributions to conception and design, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2021 Fuyo Kimura et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
